Fierce Pharma | Are Metformin Recalls Just The Start? Valisure Ceo Calls For Independent Foreign Drug Tests Amid Covid-19

Fierce Pharma released an article titled, "Are Metformin Recalls Just The Start? Valisure CEO Calls For Independent Foreign Drug Tests Amid Covid-19." The article highlights Valisure's CEO David Light testifying during a Senate Finance Committee hearing about the significant flaws in the FDA's ability to adequately inspect drugs produced by foreign manufacturers and might cause quality concerns in the U.S. supply for years to come.

View the full article via Fierce Pharma here.

Fierce Pharma | Are Metformin Recalls Just The Start? Valisure Ceo Calls For Independent Foreign Drug Tests Amid Covid-19

June 3, 2020

Fierce Pharma released an article titled, "Are Metformin Recalls Just The Start? Valisure CEO Calls For Independent Foreign Drug Tests Amid Covid-19." The article highlights Valisure's CEO David Light testifying during a Senate Finance Committee hearing about the significant flaws in the FDA's ability to adequately inspect drugs produced by foreign manufacturers and might cause quality concerns in the U.S. supply for years to come.

View the full article via Fierce Pharma here.

Fierce Pharma | Are Metformin Recalls Just The Start? Valisure Ceo Calls For Independent Foreign Drug Tests Amid Covid-19

Fierce Pharma released an article titled, "Are Metformin Recalls Just The Start? Valisure CEO Calls For Independent Foreign Drug Tests Amid Covid-19." The article highlights Valisure's CEO David Light testifying during a Senate Finance Committee hearing about the significant flaws in the FDA's ability to adequately inspect drugs produced by foreign manufacturers and might cause quality concerns in the U.S. supply for years to come.

View the full article via Fierce Pharma here.

Fierce Pharma released an article titled, "Are Metformin Recalls Just The Start? Valisure CEO Calls For Independent Foreign Drug Tests Amid Covid-19." The article highlights Valisure's CEO David Light testifying during a Senate Finance Committee hearing about the significant flaws in the FDA's ability to adequately inspect drugs produced by foreign manufacturers and might cause quality concerns in the U.S. supply for years to come.

View the full article via Fierce Pharma here.

SIGN UP FOR THE VALISURE NEWSLETTER 

Sign up to stay updated with Valisure announcements, relevant industry news, company updates, and more. 

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.